Torrent Pharma, based in Ahmedabad, is approaching the acquisitions in India as part of its plans to enter the first three drug producers in a span of three or five years. Currently in seventh position for market share, Torrent has significantly reduced its operations in India in the last five years with Bot-on agreements for the main brands and small companies.For Fy25, Torrent had sales of RS 11,516 crores, of which India contributed with 6,393 RS crores. In the first interaction with the media following the announcement of his new role starting from 1 August, Aman Mehta, CEO designed at Torrent Pharma, told Et that the commitment for the Indian market remains stronger than ever.
“Being among the first three seems to be an ambitious but realistic goal,” he said. “Even with some of the structural changes that have been happening or have occurred in recent years, we believe that the intrinsic demand of the Indian pharmaceutical market will not change”.Its trust derives from constant growth in the Indian market compared to those like us or Europe that have been under pressure due to regulatory challenges and a drop at the head of the prices of generic drugs. On a total annual moving base of 12 months (Mat), the Indian pharmaceutical market grew by 7.2% to RS 2.29 Lakh Crore ($ 26.7 billion) in May. This growth is guided by a mix of drugs for heart problems, gastrointestinal products, anti-infectious, anti-diabetes, vitamins and respiratory problems.
But for Torrent, the task of taking the third degree will be difficult. Torrent must have a faster growth rate to overthrow giants such as Cipla, Alkem and Scores Pharma. Sun Pharma and Abbott guide the stack like the first two in the Indian market.
The growth strategy guided by Torrent’s business is already at stake. In 2022, the company paid 2,000 RS for the care of the curatio healthcare, producers of cosmetic dermatology brands. More recently in December, he has put a series of new generation medicines in his hand to treat diabetes from the German drug producer Boehringer Ingelheim. A year later, in 2023, Torrent approached the purchase of Cipla for a bold agreement from $ 7 billion. Although it could not be officially confirmed, the talks failed to the failure to correspond to the evaluation.
Torrent has also been appointed non -nominee to acquire a majority participation in JB Pharma by the private equity company KKR, but that agreement was also canceled, at least temporarily. Mehta, who guided most of the business discussions for Torrent, says that the company is in a stronger position to further invest and grow business.
Sheettal Sadale, VP, Pharmatrac, a data intelligence company that keeps trace of medical sales, said that the revenues of Torrent Pharma have grown by 1.6 times in the last five years, with cardiac treatments that make up a quarter of its internal sales. He added that the strategic acquisitions helped Torrent to consolidate his position in pain -relieving drugs, gastrointestinal medicines and skin care interval.
Over the past four years, Torrent has expanded his force on the field. From 3,600, this can now double to 7000 medical representatives this year, which Mehta has called “methodical expansion for a better territorial scope”.
